TITLE

Inspection or harmonisation?

AUTHOR(S)
Baker, John; Gibson, Jane
PUB. DATE
October 2006
SOURCE
ICIS Chemical Business;10/9/2006, Vol. 1 Issue 38, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Editorial
ABSTRACT
The article comments on the reliance of western pharmaceutical firms on publicly funded inspections of non-U.S. and non-European Union production facilities to ensure imported quality products to use in their drugs. During the CPhl event in Paris, France, the Synthetic Organic Chemical Manufacturers Association and the European Fine Chemicals Group warned about the lack of inspections and the danger of importing pharmaceutical ingredients from plants not approved to Good Manufacturing Practice.
ACCESSION #
22905414

 

Related Articles

  • Trends in: Foreign Inspections. Drakulich, Angie // Pharmaceutical Technology;Nov2008, Vol. 32 Issue 11, p28 

    The article discusses the result of the survey conducted by the European Federation of Pharmaceutical Industries and Associations (EFPIA) on the company spending on regulatory inspections. The survey revealed that 33% of manufacturing sites worldwide had at least three inspections in 2007, where...

  • Conference call.  // R&D Magazine;May2003, Vol. 45 Issue 5, p51 

    Presents information on the Open Conference on Analytical Methods and General United States Pharmacopeia Topics in Philadelphia, Pennsylvania in June 2003. Purpose of the meeting; Sponsors of the meeting; List of personnel who are interested in the meeting.

  • CDER Forms Up Pharmaceutical Inspectorate. Haystead, John // Pharmaceutical Technology;Apr2003, Vol. 27 Issue 4, p15 

    Reports that the U.S. Food and Drug Administration's Center for Drug Evaluation and Research has formed a uniquely-focused group of specialists to conduct inspections of pharmaceutical manufacturing facilities. Need of specialized knowledge and skills in the use of increasingly-advanced...

  • Overhauling Compliance and GMPs. Wechsler, Jill // Pharmaceutical Technology;Apr2003, Vol. 27 Issue 4, p22 

    Discusses the U.S. Food and Drug Administration's initiative to develop a risk-based approach to good manufacturing practice regulation of the pharmaceutical industry. Changes in plant inspection policies; Establishment of pharmaceutical inspectorate; Reduction in disputes involving inspection...

  • Govt. keen on having domestic regulators during US-FDA inspections.  // FRPT- Chemical Snapshot;1/25/2015, p2 

    The article reports on the move of the Indian government to request the U.S. Food and Drug Administration (FDA) to allow its domestic regulators during inspections of pharmaceutical companies.

  • Maintaining the Cold Chain. Forcinio, Hallie // Pharmaceutical Technology;Mar2006, Vol. 30 Issue 3, p44 

    The article reports on the Parenteral Drug Association's issuance of Technical Report No. 39 "Cold Chain Guidance for Medicinal Products: Maintaining the Quality of Temperature-Sensitive Medicinal Products through the Transportation Environment". The guidance discusses how to develop protective...

  • European Generic Firms Mount Biosimilars Push. O'Donnell, Peter // BioWorld International;12/5/2007, Vol. 12 Issue 49, p4 

    This article reports on a public campaign that was launched by the European generic medicines association European Generic Medicines Association (EGA) to win acceptance of biosimilars or the generic versions of biotechnology medicines. The guide being distributed by generic companies is...

  • Pharmaceutical company practice. Simmonds, Heather // Practice Nurse;2/9/2007, Vol. 33 Issue 3, p20 

    The article offers information on the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry. The Code covers the promotion of medicines for prescribing, as well as the provision of information about prescription-only medicines. It reflects and...

  • GPhA outlines key initiatives for generics industry post-election. Kirsche, Michelle L. // Drug Store News;11/22/2004, Vol. 26 Issue 16, p24 

    Lists the priorities of the Generic Pharmaceutical Association for the pharmaceutical industry in the U.S. Establishment of a flexible and affordable biogeneric approval process; Initiative to authorize generics; Prescription drug importation.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics